Cubist Systematic Strategies’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cubist Systematic Strategies’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-800	Closed	-$5K	–	5056
2022 Q2	$5K	Buy	800 +432	+117%	+$2.44K	﹤0.01%	4299
2022 Q1	$2K	Buy	+368	New	+$2.07K	﹤0.01%	3519
2021 Q3	–	Sell	-328	Closed	-$2K	–	3336
2021 Q2	$2K	Buy	+328	New	+$2.17K	﹤0.01%	2891
2017 Q2	–	Sell	-1,874	Closed	-$45K	–	2019
2017 Q1	$45K	Sell	1,874 -821	-30%	-$20.5K	﹤0.01%	1487
2016 Q4	$87K	Buy	+2,695	New	+$115K	0.01%	1517
2016 Q3	–	Sell	-3,194	Closed	-$135K	–	1999
2016 Q2	$135K	Buy	3,194 +1,905	+148%	+$104K	0.01%	1447
2016 Q1	$85K	Sell	1,289 -587	-31%	-$30.6K	﹤0.01%	1421
2015 Q4	$117K	Buy	+1,876	New	+$132K	0.01%	1483
2015 Q2	–	Sell	-1,753	Closed	-$164K	–	2192
2015 Q1	$164K	Buy	+1,753	New	+$149K	0.01%	1588
2014 Q3	–	Sell	-4,280	Closed	-$246K	–	1968
2014 Q2	$246K	Buy	+4,280	New	+$217K	0.01%	1054

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Cubist Systematic Strategies's MACK Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2022, closing a stake of 800 shares — an estimated $5K sold.

Cubist Systematic Strategies first reported a position in MACK in Q2 2014 and held it in 10 quarters. The position peaked at $246K in Q2 2014. 41 funds tracked by Wall St. Rank hold MACK as of Q3 2022.

Cubist Systematic Strategies reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 800 Merrimack Pharmaceuticals, Inc. shares in Q3 2022, an estimated $5K.
Cubist Systematic Strategies first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 10 quarters.
Cubist Systematic Strategies's Merrimack Pharmaceuticals, Inc. position peaked at $246K in Q2 2014.
41 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.